Somatic deletions of the PolyA Tract in the 39 untranslated region of epidermal growth factor receptor are common in microsatellite instability-high endometrial and colorectal carcinomas

Archives of Pathology and Laboratory Medicine

Volumn 136, Issue 5, 2012, Pages 510-516

  Ma, Deqin ^a   Chen, Zhao ^a   Nero, Christopher ^b   Patel, Keyur P ^a   Daoud, Emad M ^a   Cheng, Hanyin ^a   Djordjevic, Bojana ^a   Broaddus, Russell R ^a   Medeiros, L Jeffrey ^a   Rashid, Asif ^a   Luthra, Rajyalakshmi ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Texas Children's Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; POLYADENYLIC ACID; RAS PROTEIN;

3' UNTRANSLATED REGION; ARTICLE; COLORECTAL TUMOR; ENDOMETRIUM TUMOR; FEMALE; GENE DELETION; GENETICS; HUMAN; MICRODISSECTION; MICROSATELLITE INSTABILITY; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PROTO ONCOGENE; REAL TIME POLYMERASE CHAIN REACTION;

3' UNTRANSLATED REGIONS; BASE SEQUENCE; COLORECTAL NEOPLASMS; ENDOMETRIAL NEOPLASMS; FEMALE; GENES, ERBB-1; HUMANS; MICRODISSECTION; MICROSATELLITE INSTABILITY; MOLECULAR SEQUENCE DATA; MUTATION; POLY A; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; SEQUENCE DELETION;

EID: 84860600206     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2010-0638-OA     Document Type: Article

References (30)

1. Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001;37(suppl 4):S3-S8.
2. Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell. 2002;110(6):669-672.
3. Lemmon MA. Ligand-induced ErbB receptor dimerization. Exp Cell Res. 2009;315(4):638-648.
4. Oza AM, Eisenhauer EA, Elit L, et al. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol. 2008;26(26):4319-4325.
5. Vallbohmer D, Lenz HJ. Epidermal growth factor receptor as a target for chemotherapy. Clin Colorectal Cancer. 2005;5(suppl 1):S19-S27.
6. Cunningham MP, Essapen S, Thomas H, et al. Coexpression of the IGF-IR, EGFR and HER-2 is common in colorectal cancer patients. Int J Oncol. 2006; 28(2):329-335.
7. Inada S, Koto T, Futami K, Arima S, Iwashita A. Evaluation of malignancy and the prognosis of esophageal cancer based on an immunohistochemical study (p53, E-cadherin, epidermal growth factor receptor). Surg Today. 1999;29(6):493-503.
8. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001;37(suppl 4):S9-S15.
9. Roberts RB, Min L, Washington MK, et al. Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. Proc Natl Acad Sci U S A. 2002; 99(3):1521-1526.
10. Vasei M, Modjtahedi H, Ale-Booyeh O, et al. Amplification and expression of EGFR and ERBB2 in Wilms tumor. Cancer Genet Cytogenet. 2009;194(2):88-95.
11. Yuan Z, Shin J, Wilson A, et al. An A13 repeat within the 39-untranslated region of epidermal growth factor receptor (EGFR) is frequently mutated in microsatellite instability colon cancers and is associated with increased EGFR expression. Cancer Res. 2009;69(19):7811-7818.
12. Rego RL, Foster NR, Smyrk TC, et al. Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. Br J Cancer. 2010;102(1):165-172.
13. Baranovskaya S, Martin Y, Alonso S, et al. Down-regulation of epidermal growth factor receptor by selective expansion of a 59-end regulatory dinucleotide repeat in colon cancer with microsatellite instability. Clin Cancer Res. 2009;15(14):4531-4537.
14. Ballard L, Adams P, Bao Y, et al. Strategies for genotyping: effectiveness of tailing primers to increase accuracy in short tandem repeat determinations. J Biomol Tech. 2002;13(1):20-29.
15. Luthra R, Singh RR, Luthra MG, et al. MicroRNA-196a targets annexin A1: a microRNA-mediated mechanism of annexin A1 downregulation in cancers. Oncogene. 2008;27(52):6667-6678.
16. Zuo Z, Chen SS, Chandra PK, et al. Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Mod Pathol. 2009; 22(8):1023-1031.
17. Conne B, Stutz A, Vassalli JD. The 39 untranslated region of messenger RNA: a molecular 'hotspot' for pathology? Nat Med. 2000;6(6):637-641.
18. Kondo S, Kubota S, Eguchi T, et al. Characterization of a mouse ctgf 39-UTR segment that mediates repressive regulation of gene expression. Biochem Biophys Res Commun. 2000;278(1):119-124.
19. Puga I, Lainez B, Fernandez-Real JM, et al. A polymorphism in the 39 untranslated region of the gene for tumor necrosis factor receptor 2 modulates reporter gene expression. Endocrinology. 2005;146(5):2210-2220.
20. Koenders PG, Peters WH, Wobbes T, Beex LV, Nagengast FM, Benraad TJ. Epidermal growth factor receptor levels are lower in carcinomatous than in normal colorectal tissue. Br J Cancer. 1992;65(2):189-192.
21. Koenders PG, Beex LV, Kienhuis CB, Kloppenborg PW, Benraad TJ. Epidermal growth factor receptor and prognosis in human breast cancer: a prospective study. Breast Cancer Res Treat. 1993;25(1):21-27.
22. de Wit PE, Moretti S, Koenders PG, et al. Increasing epidermal growth factor receptor expression in human melanocytic tumor progression. J Invest Dermatol. 1992;99(2):168-173.
23. Hemmings C, Broomfield A, Bean E, Whitehead M, Yip D. Immunohistochemical expression of EGFR in colorectal carcinoma correlates with high but not low level gene amplification, as demonstrated by CISH. Pathology. 2009; 41(4):356-360.
24. Scartozzi M, Bearzi I, Mandolesi A, et al. Epidermal growth factor receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecancetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis. BMC Cancer. 2009;9:303.
25. Fakih MM. KRAS mutation screening in colorectal cancer: from paper to practice. Clin Colorectal Cancer. 2010;9(1):22-30.
26. Italiano A, Hostein I, Soubeyran I, et al. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. Ann Surg Oncol. 2010;17(5):1429-1434.
27. Lievre A, Blons H, Laurent-Puig P. Oncogenic mutations as predictive factors in colorectal cancer. Oncogene. 2010;29: 3033-3043.
28. Lopez-Crapez E, Mineur L, Emptas H, Lamy PJ. KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity? Br J Cancer. 2010;102(6):1074-1075.
29. Modjtahedi H, Essapen S. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anticancer Drugs. 2009;20(10):851-855.
30. Ishii S, Xu YH, Stratton RH, Roe BA, Merlino GT, Pastan I. Characterization and sequence of the promoter region of the human epidermal growth factor receptor gene. Proc Natl Acad Sci U S A. 1985;82:4290-4294.